Exploiting autoimmunity unleashed by low‐dose immune checkpoint blockade to treat advanced cancer-Reference-Cited by-同舟云学术

Exploiting autoimmunity unleashed by low‐dose immune checkpoint blockade to treat advanced cancer

Published:2019-10-07 Issue:6 Volume:90 Page:
ISSN:0300-9475
Container-title:Scandinavian Journal of Immunology
language:en
Short-container-title:Scand J Immunol

Author:

Bakacs Tibor¹^ORCID,Moss Ralph W.²,Kleef Ralf³,Szasz Marcell A.⁴,Anderson Colin C.⁵

Affiliation:

1. PRET Therapeutics Ltd. Budapest Hungary

2. Moss Reports Blue Hill Maine

3. Immunology & Integrative Oncology Kleef Hyperthermie Vienna Austria

4. Cancer Centre Semmelweis University Budapest Hungary

5. Departments of Surgery and Medical Microbiology & Immunology Alberta Diabetes InstituteAlberta Transplant InstituteUniversity of Alberta Edmonton Alberta Canada

Publisher

Wiley

Subject

Immunology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/sji.12821

Reference87 articles.

1. Control of In Vivo Collateral Damage Generated by T Cell Immunity

2. Targeting Immune Checkpoints in Cancer Therapy

3. BakacsT KristofK MehrishiJN et al.The fallacy of tumor immunology. 2016 2016 [cited; Available from: arXiv:1601.02404v2.

4. Immune Checkpoint Blockade in Cancer Therapy

5. Immune Checkpoint Blockade in Cancer Therapy

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An immunomodulating peptide with potential to suppress tumour growth and autoimmunity;Scientific Reports;2023-11-13

2. Risk factors and prognostic relationship between EGFR gene mutation and immunotherapy-related endocrine adverse events in lung cancer;Materials Express;2023-09-01

3. Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma;Frontiers in Oncology;2022-12-22

4. Immune-related adverse events: A bibliometric analysis;Frontiers in Immunology;2022-12-15

5. Immunogenomic correlates of immune-related adverse events for anti–programmed cell death 1 therapy;Frontiers in Immunology;2022-11-25